|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of Human Genome and Multifactorial
Disease, Istituto di Tecnologie, Biomediche Avanzate, Consiglio
Nazionale delle Ricerche, Segrate (MI); Istituto di Medicina Molecolare
"Angelo Nocivelli," and Clinica Pediatrica, Universita di Brescia,
Italy; Children's Bone Marrow Transplant Unit, Newcastle General
Hospital, Newcastle-upon-Tyne; University of Manchester, Academic
Unit of Child Health, St Mary's Hospital, Manchester, United
Kingdom; Department of Pediatrics, The National Hospital, Oslo,
Norway; Lauterberg Center for General and Tumor Immunology, Hebrew
University-Hadassah Medical School, Jerusalem; Pediatric
Hematology-Oncology, Sheba Medical Center, Tel Hashomer and Sackler
School of Medicine, Tel Aviv University, Tel Aviv, Israel; Queen Silvia
Children's Hospital, Göteborg, Sweden; Department of Pediatrics
and Ulm Germany Transfusion Medicine, University of Ulm, Ulm, Germany;
Pediatric Immunology, Mother and Child Health Institute, Belgrade,
Yugoslavia; University Childrens' Hospital, University of Zurich,
Zurich, Switzerland; Institute of Medical Technology, University of
Tampere, and Tampere University Hospital, Tampere, Finland; Department
of Pediatrics, Child Health Research Center, University of Texas
Medical Branch, Galveston, TX; Department of Immunology, St Jude
Children's Research Hospital, Memphis, TN; Immunobiology Center and
Ruttenberg Cancer Center, Mount Sinai School of Medicine of New York
University, New York, NY; Children's Hospital Medical Center,
Cincinnati, OH; Division of Hematology/Oncology/Immunology, Children's
Cancer Research Center, University of Texas Health Science Center, San
Antonio, TX; Pediatric Rheumatology Division, Emory University School
of Medicine, Atlanta, GA; Department of Pediatrics, University of
Washington School of Medicine, Seattle, WA; and Health Sciences Center,
University of Manitoba, Canada.
Severe combined immunodeficiency (SCID) comprises a heterogeneous
group of primary immunodeficiencies, a proportion of which are due to
mutations in either of the 2 recombination activating genes
(RAG)-1 and -2, which mediate the process of V(D)J
recombination leading to the assembly of antigen receptor genes. It is
reported here that the clinical and immunologic phenotypes of patients bearing mutations in RAGs are more diverse than previously
thought and that this variability is related, in part, to the specific type of RAG mutation. By analyzing 44 such patients from 41 families, the following conclusions were reached: (1) null mutations on both alleles lead to the T-B-SCID phenotype; (2) patients manifesting classic Omenn syndrome (OS) have missense mutations on at least one
allele and maintain partial V(D)J recombination activity, which
accounts for the generation of residual, oligoclonal T-lymphocytes; (3)
in a third group of patients, findings were only partially compatible
with OS, and these patients, who also carried at least one missense
mutation, may be considered to have atypical SCID/OS; (4) patients with
engraftment of maternal T cells as a complication of a transplacental
transfusion represented a fourth group, and these patients, who often
presented with a clinical phenotype mimicking OS, may be observed
regardless of the type of RAG gene mutation. Analysis of
the RAG genes by direct sequencing is an effective way to
provide accurate diagnosis of RAG-deficient as opposed to
RAG-independent V(D)J recombination defects, a distinction that cannot be made based on clinical and immunologic phenotype alone.
(Blood. 2001;97:81-88) The process of V(D)J recombination, leading to the
assembly of genes coding for immunoglobulins and T-cell receptors
(TCR), is central to the differentiation of B and T cells, to the
establishment of a functional immune system, and to its ability to
respond to antigenic challenge.1
All the immunoglobulin and TCR protein chains consist of 2 structural
domains, the constant and the variable regions; the latter are
responsible for the specific binding to antigen. V(D)J recombination is
the process leading to the generation of variable domains through the
assembly of one segment each from a set of variable (V), joining
(J), and, in some cases, diversity (D) subgenic elements.2
Rearrangement is directed by recombination signal sequences that
flank each antigen receptor gene segment. These recombination signal
sequences consist of a heptamer sequence (CACAGTG), directly adjacent
to the coding element, and a nonamer element (ACAAAACC), separated from
the heptamer by a spacer of either 12 or 23 base pairs.3,4
Efficient recombination occurs between a pair of gene elements with
recombination signal sequences that have different spacer lengths, the
so-called 12/23 rule.
This process is carried out by several molecules that act in concert to
create the diversity of the antigen receptor repertoire. Recombination
activating genes (RAG-1 and RAG-2) play a
fundamental role by initiating the "cut-and-paste" process leading
to the assembling of the V, (D), and J segments, which together form the variable portion of the receptors.5,6 So far, the
RAG genes are the only components of the gene
rearrangement apparatus in which mutations leading to primary
immunodeficiencies in humans have been described. This is at odds with
investigations in the mouse, in which several spontaneously occurring
or artificially created mutations in genes involved in DNA repair and
V(D)J recombination, including those of the DNA-PK complex,
xrcc4 and DNA ligase IV, have been demonstrated
to cause severe combined immunodeficiencies (SCID) with low numbers of
both B- and T-lymphocytes (T-B-SCID).7-14
Gene targeting of the rag-1 and rag-2 in mice
results in a complete absence of both B- and T-lymphocytes, whereas
natural killer cells, which do not rearrange antigen receptor genes
during their maturation, are not affected.15,16 No murine
model of partial inactivation of RAG function is
available at present. In agreement with the mouse model, we have
recently demonstrated that T-B- SCID in human is often due to
RAG gene mutations.17 Patients with
SCID secondary to RAG mutations may have Omenn
syndrome (OS),18 a rare combined immune deficiency
characterized by the presence of a substantial number of oligoclonal,
activated T cells, and the lack of B lymphocytes, associated with
particular clinical features (generalized erythroderma,
lymphadenopathy, hepatosplenomegaly, increased occurrence of
life-threatening infections).19-21 On the basis of our
findings, obtained in a limited number of RAG-deficient cases, we hypothesized that in humans the persistence of partial RAG activity could be responsible for OS, whereas mutations
that completely abolish RAG function could give rise to T-B-
SCID.17,18,22 A role for nongenetic factors in the
pathogenesis of OS cannot be ruled out. In addition, the extent to
which a limited but detectable RAG activity can allow
partial maturation of T or B cells has not yet been defined.
Here we report a large series of immunodeficient patients with
RAG defects. Analysis of the type and site of the
RAG mutations in relation to their clinical presentation and
immunologic phenotype supports our previous hypothesis that partial
RAG activity, allowing limited recombination events to
occur, is the major determinant for the presence of a substantial
number of oligoclonal T cells in OS. Furthermore, we have identified
RAG defects in a cohort of patients with some, but not all,
the clinical and immunologic features of OS, a condition referred to
here as "atypical SCID/OS." Interestingly, missense mutations were
overrepresented in patients with atypical SCID/OS, as they were in
patients with OS. Finally, we have demonstrated that engraftment of
maternal T cells into fetuses with RAG deficiency,
regardless of the type and site of mutations, may result in a clinical
and immunologic phenotype that mimics OS. Taken together, these
findings suggest that RAG-dependent immunodeficiency covers
a spectrum broader than previously thought and that the clinical
picture is partly dependent on the specific mutation in the
RAG genes.
Patients
Mutation analysis at the RAG-1 and RAG-2
loci
More than 150 patients with SCID or OS, and negative for other
genes known to be involved in SCID, were analyzed for
RAG mutations. Forty-five patients from 41 unrelated
families with RAG defects are reported in this paper (Table
1; Figure
1). Thirteen of them have been
previously reported (patients 3, 9a with his brother 9b, 12 14, 20 in
reference 17; patients 16b, 21, 31, 33-35, 37 in reference 18; patient
26 in reference 24). On the basis of the clinical presentation (Table
2) and the immunologic data (Table
3), we divided our patients into 4 subgroups. Nine patients (patients 1 to 9a) were classified as affected
with T-B- SCID, 17 patients (27 to 41 and 16b) were diagnosed with
classical OS (in 3 of these patients, maternal fetal engraftment
[MFT] was not determined), 7 patients (patients 9b-15) were diagnosed
with SCID with MFT, and 11 patients (patients 16a-26) were thought to
have atypical SCID/OS (including 4 patients in whom MFT was not
determined).
RAG mutations in T-B- SCID Among 9 patients with T-B- SCID, 6 carried mutations in the RAG-1 gene, and 3 carried mutations in the RAG-2 gene. Of these 9 patients, 6 were homozygous for either nonsense (patients 1, 2, 5) or frameshift (patients 4, 6, 8) mutations and were therefore predicted to lack expression of functional protein. One additional patient (patient 7) was a compound heterozygote for 2 severe mutations; furthermore, patient 3 carried a nonsense mutation on one RAG-1 allele and a missense mutation (E722K) on the other allele, previously shown to be completely inactive.17 Only patient 9a in this series was homozygous for a RAG-2 gene missense mutation (C478Y), the product of which was dead for function.17RAG mutations in Omenn syndrome Seventeen patients from 16 unrelated families (including patient 16b, whose brother was classified as affected with atypical SCID/OS) were defined as having classic OS. In 13 of these families, the mutation affected the RAG-1 gene, and in 3 it affected the RAG-2 gene. Seven patients from 6 families had homozygous mutations, whereas the remaining 10 unrelated patients were compound heterozygotes. All patients carried at least one missense mutation. Eleven patients (27-30b, 32, 36, 38-41) from 10 families in this series have not been previously reported and are described here in more detail. Of these, 4 were homozygous for a missense mutation (patients 27, 28, 30, 41). The other 6 patients were compound heterozygotes: 2 of them (patients 36 and 40) had missense mutations on both alleles; 2 (patients 29 and 32) had one missense and one nonsense mutation. The remaining 2 previously unreported patients (patients 38 and 39) had one novel missense mutation on one RAG-1 allele and a 2-bp deletion on the other. Compound heterozygosity for a missense mutation and for the same 2-bp deletion was detected also in patient 21, who has been previously described.18 Interestingly, all 3 patients with the 2-bp deletion were of Balkan (Serbian or Albanian) origin.RAG mutations in SCID with MFT Seven patients with SCID and MFT were identified through this study. Of these, as shown in Table 1, 5 had RAG-1 and 2 had RAG-2 gene mutations. Three patients were homozygous for severe mutations: nonsense mutations in the RAG-1 gene were detected in patients 13 and 14, whereas a 1-bp deletion in the RAG-1 gene was found in patient 15. Patient 12 was a compound heterozygote for a nonsense and a missense (R624H) mutation in the RAG-1 gene; the remaining 3 patients were homozygous for missense mutations in either the RAG-1 (patient 11) or the RAG-2 (patients 10 and 9b) gene. The missense mutations of patients 9b and 12 lead to a nonfunctional protein, whereas the functional consequences of the remaining missense mutations are at present undetermined.RAG mutations in patients with atypical SCID/OS Altogether, 11 patients (including patient 16a, whose brother was diagnosed as affected with OS) were classified as having atypical SCID/OS, based on their clinical and immunologic phenotypes. Four of these patients (patients 16a, 20, 21, 26) have been previously reported.17,18,24 Patient 16b had the same homozygous missense RAG-1 mutation as did his brother. The remaining 7 were either compound heterozygotes for 2 missense mutations in the RAG-1 gene (patients 17-19, 22, 25) or homozygous for missense mutations in the RAG-1 (patient 23) or the RAG-2 (patient 24) gene.Analysis of the clinical and immunologic phenotypes For each patient included in the study, clinical and immunologic data are shown in Tables 2 and 3, respectively. Cutaneous manifestations (documented in 31 patients), failure to thrive (n = 30), and protracted diarrhea (n = 27) were the most common clinical features in our series of 44 patients with RAG defects. However, though common manifestations of SCID (failure to thrive, pneumonia, and protracted diarrhea) were similarly documented in all subgroups, other signs were more common in specific cohorts. In particular, generalized erythroderma was documented in 15 of 17 patients with OS and in 7 of 11 patients with atypical SCID/OS SCID, but only in 2 of 7 patients with SCID and MFT and in none of the 7 patients with T-B- SCID. Lymphadenopathy was found only in patients with SCID and MFT (5 of 7 patients) and in patients with OS, the diagnosis of which required the presence of this clinical feature. Hepatomegaly was demonstrated in all 17 patients with OS and was less common in the other subgroups (1 of 9 patients with T-B- SCID; 2 of 7 patients with SCID with MFT; 4 of 11 patients with atypical SCID/OS).Analysis of the clinical and immunologic phenotypes associated with
SCID and MFT revealed a particularly high degree of heterogeneity. Although all 7 patients in this subgroup had failure to thrive, signs
resembling OS (erythroderma, skin rash, lymphadenopathy, hepatosplenomegaly) were only present in 5 of them (patients 9b, 12-15). These patients also had higher proportions of circulating T-lymphocytes than patients 10 and 11. Analysis of total lymphocyte and
eosinophil counts and of lymphocyte subset distribution and functions
in the 4 subgroups of RAG-deficient patients is reported in
Table 4.
Lymphopenia was documented in a particularly high proportion of patients with T-B- SCID and, to a lesser degree, in patients with atypical SCID/OS: 6 of 8 patients with T-B- SCID and 6 of 11 patients with atypical SCID/OS for which enough information was available had a total lymphocyte count of less than 1500 cells/µL. In contrast, only 2 of 7 patients with SCID and MFT and 4 of 14 patients with OS had such low counts. A high variability in the total lymphocyte count was documented in these latter 2 groups. Patients with OS had a normal proportion of CD3+ lymphocytes (65.4% ± 5.3%, mean ± SE) compared to normal controls (71% ± 6%). In all the other groups, a low proportion of CD3+ cells was documented, with intermediate values in the atypical SCID/OS (32.3% ± 7.2%) and in the SCID with MFT (23.9% ± 9.3%) groups versus patients with T-B- SCID, who necessarily had very low T-cell counts (0.9% ± 0.5%). Data on the expression of activation markers (DR, CD45R0) were available for the subgroups of patients with OS and atypical SCID/OS. In particular, both groups showed increased percentages of DR+ cells (OS, 52.3% ± 6%; atypical SCID/OS, 40.5% ± 8.4%) compared with controls (20% ± 3%). Furthermore, the proportion of CD45R0+ cells within CD4+ lymphocytes was markedly increased in patients with OS (94.8% ± 1.9%) and in patients with atypical SCID/OS (95.5% ± 2%) versus age-matched healthy controls (21% ± 9%). All 4 groups of RAG-deficient patients had very low proportions of CD19+ cells; however, residual (more than 3%) B cells were found in 5 of 11 patients with atypical SCID/OS and in 3 of 16 patients with OS. Although the proportion of CD16+ natural killer cells was increased in all subgroups compared with controls, highest values were found in patients with T-B- SCID (72.9% ± 5.7%), SCID with MFT (53.6% ± 8.2%), and atypical SCID/OS (48.5% ± 7%) versus OS (21.6% ± 5.3%). The proliferative response to PHA was markedly diminished in all subgroups; however, residual proliferation (greater than 104 cpm) was found in 2 of 6 patients with T-B- SCID, 4 of 6 patients with SCID and MFT, 4 of 11 patients with atypical SCID/OS, and 4 of 16 patients with OS. Eosinophilia, a well-known feature of OS, was also observed in patients with atypical SCID/OS and, to a lesser degree, in patients with SCID and MFT, but not in patients with T-B- SCID. Genotype-to-phenotype correlation The different clinical picture seen in patients with defects in the same gene could be caused by the specific mutations, by other genetic factors, or by epigenetic mechanisms. Mutation analysis at the RAG loci failed to indicate a specific association of any of the 4 clinical and immunologic subgroups with the exclusive presence of mutations in either the RAG-1 or the RAG-2 gene. In contrast, type of mutation (missense vs nonsense or frameshift) has emerged as a major determinant of the clinical and immunologic phenotype. As shown in Figure 1 and in Table 5, 15 of 18 mutant alleles identified in patients with T-B- SCID were presumably null and were represented by nonsense (n = 8) or frameshift (n = 7) mutations, whereas the remaining 3 missense alleles are functional null mutants.17 This contrasts the predominance of missense mutations in patients with OS (in whom they accounted for 29 of 34 alleles) and in patients with atypical SCID/OS (in which missense mutations accounted for 20 of 22 alleles). An even distribution of missense and severe (nonsense and frameshift) mutations was documented in patients with SCID and MFT.
To elucidate the role of specific RAG abnormalities, we analyzed homozygous or hemizygous patients with mutations affecting the same codon. These include 5 patients from 4 unrelated families in whom the RAG-2 R229 codon is affected, one with a hemizygous R229Q (patient 20), one homozygous for R229Q (patient 26), one homozygous for R229W (patient 24), and 2 cousins homozygous for R229W (patients 30a and 30b). The 2 brothers had a complete picture of OS, whereas the other 3 were classified as having atypical SCID/OS. In addition, homozygosity for missense mutations at RAG-1 residue A444 was found in 2 patients (23 and 41), one with a full picture of OS and the other with a diagnosis of atypical SCID/OS. When only homozygous patients are examined, there is no overlap between SCID and OS. Heterozygosity for a biochemically inactive single amino acid substitution (E722K in RAG-1) was shared by one patient with T-B- SCID (patient 3) and another patient with OS (patient 38), but these patients differed for the second mutation. Two different missense mutations affecting codon 624 (R624H in patient 12 and R624C in patient 39) were found in a patient with SCID-MFT and in one patient with OS. Although these data confirm that OS is caused by mutations that are permissive for RAG protein expression (and presumably function), they also indicate that a similar mechanism may apply to RAG-dependent atypical SCID/OS. It is unlikely that the distinction between these 2 forms is caused by specific differences in amino acid substitutions because patients 16a and 16b (2 siblings) had distinct phenotypes (atypical SCID/OS and OS, respectively) though sharing homozygosity for the R396C mutation in the RAG-1 gene. Furthermore, homozygosity for the R229W mutation in the RAG-2 gene also resulted in either atypical SCID/OS (as for patient 24) or in typical OS (as in siblings 30a and 30b), and the A444V mutation in the RAG-1 gene, observed in 2 unrelated Turkish patients, also resulted in either atypical SCID/OS (patient 23) or OS (patient 41). This suggests that at least some patients with atypical SCID/OS in fact have Omenn Syndromes with partial expression or "incomplete" OS or OS variants. RAG1base and RAG2base mutation databases All the reported RAG-1 and RAG-2 mutations17,18 were collected into databases called RAG1base and RAG2base. The databases contain 4 main items: identification of the patient and mutation(s), reference either to published article(s) or a submitting physician, mutation information, and data related to disease and therapy. In addition to mutations, the registries contain information about, for example, lymphocyte counts, age at diagnosis, symptoms, and putative structural consequences of the mutations. The databases were constructed according to the concepts used in BTKbase, XLA mutation registry,25 the MUTbase system.26 The RAGbases are freely accessible on the World Wide Web at http://www.uta.fi/imt/bioinfo/RAG1base and /RAG2base.
T-B- SCID is a heterogeneous group of diseases, some of which are caused by abnormalities in RAG genes.17,27 OS is also a combined immune deficiency with a peculiar immunologic and clinical phenotype that differs considerably from typical T-B- SCID but that, as previously shown, may be observed in patients with RAG mutations.18 We have previously hypothesized that, as demonstrated in other diseases, the specific type of mutation found in individual patients could be responsible, at least in part, for these differences.18,22 By investigating a larger number of patients with T-B- SCID and OS, we have shed further light on the molecular basis of RAG-dependent immunodeficiency, providing genetic evidence for the existence of 2 different classes of immune defects caused by complete or partial inactivation of RAG activity, respectively. In addition, we found an intermediate class of patients we refer to as having atypical SCID/OS, with some T (and occasionally B) cells but without the stigmata of OS. This conclusion is supported by the following findings described in this paper. When homozygous mutations are considered, patients with severe truncations or premature terminations of RAG-1 protein in both alleles (null mutations) are only found among those with classical T-B- SCID. Each patient with OS carries at least one allele with missense mutations, and most of them have missense substitutions on both alleles. In addition, though some patients with classical T-B- SCID have missense RAG-1 mutations, the biochemical studies performed so far have shown that these amino acid changes completely abrogate recombination ability and, thus, represent null alleles, whereas those found in OS maintain partial activity17,18 (Gomez et al, manuscript submitted). Through our study, we identified patients with an intermediate clinical picture, which we classified as atypical SCID/OS. With regard to their molecular basis, this category seems to be more like OS than classic SCID because all these patients carry at least one missense mutation, some of which are shared with OS patients. This conclusion is in agreement with the idea that in these patients, partial RAG activity is responsible for the development of a low number of T- (and possibly B-) lymphocytes. It can be speculated that the presence of partial RAG activity is a prerequisite for OS but that other epigenetic factors are needed to understand the disease fully. Alternatively, it is possible that individual differences result from early or delayed medical treatment. This contributes to clinical and immunologic heterogeneity, particularly because in some patients bone marrow transplantation performed very early in the course of the disease may eradicate the endogenous autoreactive T-cell clones and prevent the development of typical OS symptoms. One such example is represented in our series by patients 16a and 16b. Patient 16a underwent bone marrow transplantation at 2 months of age, in the absence of typical signs of OS, whereas his elder brother had clinical and laboratory findings of OS at 4 months of age. Finally, the possibility of the occurrence of stochastic events leading to the rearrangement of specific TCR molecules could modify the course of the disease. It has been hypothesized that some recombinational events do occur in patients with OS and with atypical SCID/OS18,21 and that they allow the differentiation of a few T- or B-cell clones to occur. Although the persistence of a limited RAG function is a prerequisite for this, the specific clinical picture shown by patients can, to some extent, be defined by further genetic or epigenetic (environmental) factors, including exposure to pathogens. Some mutations, such as the one found in patient 22, seem to be relatively mild; this patient showed a substantial number of lymphocytes in the peripheral blood. The possibility that even milder Rag mutations exist and are responsible for a less severe immunodeficiency, and possibly autoimmunity as the only manifestation, is worth investigating. Additional analysis has revealed that truncated core proteins, encompassing amino acids 384 to 1008 for RAG-1 and amino acids 1 to 387 for RAG-2, are necessary and sufficient to rearrange artificial V(D)J recombination substrates in vitro.1,28 Our study has identified 3 homozygous missense mutations (Figure 1; Table 1) (RAG-1, patient 28; RAG-2, patients 9a, 9b, 10) that do not map to the RAG core regions. We therefore conclude that a full description of the in vivo function of the RAG proteins cannot be obtained by the use of core proteins. This is supported by a recent study29 showing that the removal of dispensable regions of RAG-1 and RAG-2 impairs proper processing of recombination substrates.
We thank Lucia Susani, Massimo Littardi, Massimiliano Mirolo, and Ingrid Janz for their technical assistance. We thank Prof R. Dulbecco for encouragement and Ms Victoria Starnes for typing the manuscript.
Submitted June 8, 2000; accepted August 30, 2000.
Supported by grants from Telethon to A.V. (E0917) and L.D.N. (E.668); Biomed2 (grant CT 98-3007 to L.D.N. and K.S. and grant PL 963007 to M.V.), and by funding to K.S. from Deutsches Rotes Kreuz, Blutspendedienst Baden-Württemberg, GmbH, Stuttgart and Bundesministerium für Bildung und Forschung IZKF-Ulm C05. M.V. is a recipient of a grant from Tampere University Hospital Medical Research Fund and Finnish Academy. This article is manuscript no. 33 of the Genoma 2000/ITBA Project funded by CARIPLO.
A.V. and C.S. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anna Villa, ITBA, CNR, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy.
1. Lewis SM. The mechanism of V(D)J joining: lessons from molecular, immunological and comparative analyses. Adv Immunol. 1994;56:27-150[Medline] [Order article via Infotrieve]. 2. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302:575-581[CrossRef][Medline] [Order article via Infotrieve].
3.
Hesse JE, Lieber MR, Mizuuchi K, Gellert M.
V(D)J recombination: a functional definition of the joining signals.
Genes Dev.
1989;3:1053-1061
4.
Ramsden DA, Baetz K, Wu GE.
Conservation of sequence in recombination signal sequence spacers.
Nucleic Acids Res.
1994;22:1785-1796 5. Schatz DG, Oettinger MA, Baltimore D. The V(D)J recombination activating gene RAG-1. Cell. 1989;59:1035-1048[CrossRef][Medline] [Order article via Infotrieve].
6.
Oettinger MA, Schatz DG, Gorka C, Baltimore D.
RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination.
Science.
1990;248:1517-1523 7. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization and potential uses. Ann Rev Immunol. 1991;9:323-350[CrossRef][Medline] [Order article via Infotrieve]. 8. Nussenzweig A, Chen C, da Costa Soares V, et al. Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. Nature. 1996;382:551-555[CrossRef][Medline] [Order article via Infotrieve]. 9. Zhu C, Bogue MA, Lim DS, Hasty P, Roth DB. Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell. 1996;86:379-389[CrossRef][Medline] [Order article via Infotrieve]. 10. Gu Y, Seidl KJ, Rathbun GA, et al. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity. 1997;7:653-665[CrossRef][Medline] [Order article via Infotrieve]. 11. Bogue MA, Wang C, Zhu C, Roth DB. V(D)J recombination in Ku86-deficient mice: distinct effects on coding, signal and hybrid joint formation. Immunity. 1997;7:37-47[CrossRef][Medline] [Order article via Infotrieve]. 12. Gao Y, Sun Y, Frank KM, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell. 1998;95:891-902[CrossRef][Medline] [Order article via Infotrieve]. 13. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol. 1998;8:1395-1398[CrossRef][Medline] [Order article via Infotrieve]. 14. Frank KM, Sekiguchi JM, Seidl KJ, et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature. 1998;396:173-177[CrossRef][Medline] [Order article via Infotrieve]. 15. Shinkai Y, Rathbun G, LamK-P, et al. Rag-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D) rearrangement. Cell. 1992;68:855-867[CrossRef][Medline] [Order article via Infotrieve]. 16. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869-877[CrossRef][Medline] [Order article via Infotrieve].
17.
Schwarz K, Gauss GH, Ludwig L, et al.
Rag mutations in human B cell-negative SCID.
Science.
1996;274:97-99 18. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998;93:885-896[CrossRef][Medline] [Order article via Infotrieve]. 19. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med. 1965;273:427-432. 20. Ochs HD, Davis SD, Mickelson E, Lerner KG, Wedgwood RJ. Combined immunodeficiency and reticuloendotheliosis with eosinophilia. J Pediatr. 1974;85:463-465[CrossRef][Medline] [Order article via Infotrieve]. 21. de Saint-Basile G, Le Deist F, de Villartay JP, et al. Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest. 1991;87:1352-1359. 22. Villa A, Santagata S, Imberti L, Bozzi F, Notarangelo LD. Omenn syndrome: a disorder of Rag1 and Rag2 genes. J Clin Immunol. 1999;19:87-97[CrossRef][Medline] [Order article via Infotrieve]. 23. Macchi P, Villa Giliani S, Sacco MG, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65-68[CrossRef][Medline] [Order article via Infotrieve].
24.
Signorini S, Imberti L, Pirovano S, et al.
Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome.
Blood.
1999;94:3468-3478 25. Vihinen M, Kwan SP, Lester T, et al. Mutation of the human BTK gene coding for Bruton tyrosine kinase in X-linked agammaglobulinemia. Hum Mutat. 1999;13:280-285[CrossRef][Medline] [Order article via Infotrieve].
26.
Riikonen P, Vihinen M.
MUTbase program package for maintenance and analysis of mutation databases on World Wide Web.
Bioinformatics.
1999;15:852-859 27. Schwarz K, Villa A. Rag mutations in severe combined and Omenn's syndrome. Immunol Allergy Clin North Am. 2000;20:129-142[CrossRef]. 28. Bogue M, Roth DB. Mechanism of V(D)J recombination. Curr Opin Immunol. 1996;8:175-180[CrossRef][Medline] [Order article via Infotrieve].
29.
Steen SB, Han JO, Mundy C, Oettinger MA, Roth DB.
Roles of the "dispensable" portions of RAG-1 and RAG-2 in V(D)J recombination.
Mol Cell Biol.
1999;19:3010-3017
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S.-Y. Wong, C. P. Lu, and D. B. Roth A RAG1 Mutation Found in Omenn Syndrome Causes Coding Flank Hypersensitivity: A Novel Mechanism for Antigen Receptor Repertoire Restriction J. Immunol., September 15, 2008; 181(6): 4124 - 4130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schuetz, K. Huck, S. Gudowius, M. Megahed, O. Feyen, B. Hubner, D. T. Schneider, B. Manfras, U. Pannicke, R. Willemze, et al. An Immunodeficiency Disease with RAG Mutations and Granulomas N. Engl. J. Med., May 8, 2008; 358(19): 2030 - 2038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Raval, A. N. Kriatchko, S. Kumar, and P. C. Swanson Evidence for Ku70/Ku80 association with full-length RAG1 Nucleic Acids Res., April 1, 2008; 36(6): 2060 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Matangkasombut, M. Pichavant, D. E. Saez, S. Giliani, E. Mazzolari, A. Finocchi, A. Villa, C. Sobacchi, P. Cortes, D. T. Umetsu, et al. Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations Blood, January 1, 2008; 111(1): 271 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Simkus, P. Anand, A. Bhattacharyya, and J. M. Jones Biochemical and Folding Defects in a RAG1 Variant Associated with Omenn Syndrome J. Immunol., December 15, 2007; 179(12): 8332 - 8340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ramon-Maiques, A. J. Kuo, D. Carney, A. G. W. Matthews, M. A. Oettinger, O. Gozani, and W. Yang The plant homeodomain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2 PNAS, November 27, 2007; 104(48): 18993 - 18998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Niewolik, U. Pannicke, H. Lu, Y. Ma, L.-C. V. Wang, P. Kulesza, E. Zandi, M. R. Lieber, and K. Schwarz DNA-PKcs Dependence of Artemis Endonucleolytic Activity, Differences between Hairpins and 5' or 3' Overhangs J. Biol. Chem., November 10, 2006; 281(45): 33900 - 33909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Hill, S. S. Wang, J. R. Cerhan, S. Davis, W. Cozen, R. K. Severson, P. Hartge, S. Wacholder, M. Yeager, S. J. Chanock, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes Blood, November 1, 2006; 108(9): 3161 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Enders, P. Fisch, K. Schwarz, U. Duffner, U. Pannicke, E. Nikolopoulos, A. Peters, M. Orlowska-Volk, D. Schindler, W. Friedrich, et al. A Severe Form of Human Combined Immunodeficiency Due to Mutations in DNA Ligase IV. J. Immunol., April 15, 2006; 176(8): 5060 - 5068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wada, T. Toma, H. Okamoto, Y. Kasahara, S. Koizumi, K. Agematsu, H. Kimura, A. Shimada, Y. Hayashi, M. Kato, et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency Blood, September 15, 2005; 106(6): 2099 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, L. Quintal, A. Atkinson, B. Williams, E. Grunebaum, and C. M. Roifman Novel RAG1 Mutation in a Case of Severe Combined Immunodeficiency Pediatrics, September 1, 2005; 116(3): e445 - e449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Elkin, D. Ivanov, M. Ewalt, C. G. Ferguson, S. G. Hyberts, Z.-Y. J. Sun, G. D. Prestwich, J. Yuan, G. Wagner, M. A. Oettinger, et al. A PHD Finger Motif in the C Terminus of RAG2 Modulates Recombination Activity J. Biol. Chem., August 5, 2005; 280(31): 28701 - 28710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ege, Y. Ma, B. Manfras, K. Kalwak, H. Lu, M. R. Lieber, K. Schwarz, and U. Pannicke Omenn syndrome due to ARTEMIS mutations Blood, June 1, 2005; 105(11): 4179 - 4186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Talukder, D. D. Dudley, F. W. Alt, Y. Takahama, and Y. Akamatsu Increased frequency of aberrant V(D)J recombination products in core RAG-expressing mice Nucleic Acids Res., August 24, 2004; 32(15): 4539 - 4549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lim and K. S.J. Elenitoba-Johnson The Molecular Pathology of Primary Immunodeficiencies J. Mol. Diagn., May 1, 2004; 6(2): 59 - 83. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Jones and M. Gellert Autoubiquitylation of the V(D)J recombinase protein RAG1 PNAS, December 23, 2003; 100(26): 15446 - 15451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Peak, J. L. Arbuckle, and K. K. Rodgers The Central Domain of Core RAG1 Preferentially Recognizes Single-stranded Recombination Signal Sequence Heptamer J. Biol. Chem., May 9, 2003; 278(20): 18235 - 18240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hodges, M T Krishna, C Pickard, and J L Smith Diagnostic role of tests for T cell receptor (TCR) genes J. Clin. Pathol., January 1, 2003; 56(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yates, M. Malassis-Seris, D. Stockholm, C. Bouneaud, F. Larousserie, P. Noguiez-Hellin, O. Danos, D. B. Kohn, A. Fischer, J.-P. de Villartay, et al. Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency Blood, December 1, 2002; 100(12): 3942 - 3949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Elhasid, R. Bergman, A. Etzioni, P. D. Arkwright, M. Abinun, and A. J. Cant Autoimmunity in severe combined immunodeficiency (SCID) Blood, September 18, 2002; 100(7): 2677 - 2678. [Full Text] [PDF]
|
|
|
|
|
|
L. Li, D. Moshous, Y. Zhou, J. Wang, G. Xie, E. Salido, D. Hu, J.-P. de Villartay, and M. J. Cowan A Founder Mutation in Artemis, an SNM1-Like Protein, Causes SCID in Athabascan-Speaking Native Americans J. Immunol., June 15, 2002; 168(12): 6323 - 6329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Huye, M. M. Purugganan, M.-M. Jiang, and D. B. Roth Mutational Analysis of All Conserved Basic Amino Acids in RAG-1 Reveals Catalytic, Step Arrest, and Joining-Deficient Mutants in the V(D)J Recombinase Mol. Cell. Biol., May 15, 2002; 22(10): 3460 - 3473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yang, X.-F. Qin, D. Baltimore, and L. Van Parijs Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells PNAS, April 30, 2002; 99(9): 6204 - 6209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Arkwright, M. Abinun, and A. J. Cant Autoimmunity in human primary immunodeficiency diseases Blood, April 15, 2002; 99(8): 2694 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumaki, A. Villa, H. Asada, S. Kawai, Y. Ohashi, M. Takahashi, I. Hakozaki, E. Nitanai, M. Minegishi, and S. Tsuchiya Identification of anti-herpes simplex virus antibody-producing B cells in a patient with an atypical RAG1 immunodeficiency Blood, September 1, 2001; 98(5): 1464 - 1468. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
variant of SCID. If RAG
mutations were discovered, for each patient a questionnaire was filled
in at each participating center. Based on several criteria, patients
were classified as follows: (1) complete absence of T and B cells and
no clinical abnormalities to suggest Omenn syndrome; (2) complete
absence of B cells, but presence of autologous T cells and typical
clinical features compatible with OS; (3) patients with documented
maternal T-cell engraftment (SCID with maternal T cells); (4) patients
not fulfilling the above criteria. This group, labeled as "atypical
SCID/OS," included a few patients in whom immunologic and genetic
characterization was incomplete. Ten age-matched, healthy infants
served as controls for the analysis of immunologic data.
Approval for these studies was obtained from the institutional review
board. Informed consent was provided according to the Declaration of Helsinki.
